Stock Events

Stock Events

Omeros 

$19.16
39
+$0.04+0.21% 15:00 Today

Statistics

Day High
19.42
Day Low
18.93
52W High
19.65
52W Low
3.94
Volume
228,737
Avg. Volume
2,060,019
Mkt Cap
1.39B
P/E Ratio
9.02
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.71
-0.26
0.18
0.62
Expected EPS
0.023333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-3.35MNet Income

Analyst Ratings

34.50Average Price Target
The highest estimate is 36.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OMER. It's not an investment recommendation.
Tesla
8
TSLA
NVIDIA
7
NVDA
AMD
7
AMD
Apple
6
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals competes in the biotech space, focusing on treatments that could directly compete with Omeros' drug portfolio, especially in areas like immunology and inflammation.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals operates in similar therapeutic areas as Omeros, including rare diseases, making them direct competitors in the biotech market.
Biogen
BIIB
Mkt Cap32.63B
Biogen competes with Omeros in the biotechnology and pharmaceuticals sector, particularly in areas related to neurological conditions and rare diseases.
AMGEN
AMGN
Mkt Cap236.38B
Amgen competes across several of the same biotech and pharmaceutical areas as Omeros, including treatments for inflammatory diseases.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences competes with Omeros in the development of innovative therapies, particularly in areas like immunology.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie competes in similar therapeutic areas as Omeros, including immunology and neurological diseases, with a broad portfolio of biopharmaceuticals.
Novartis
NVS
Mkt Cap304.1B
Novartis competes with Omeros in multiple areas, including the development of treatments for rare diseases and chronic conditions.
Pfizer
PFE
Mkt Cap162.16B
Pfizer competes with Omeros through its extensive range of pharmaceutical products, including those in the immunology and inflammation sectors.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in various therapeutic areas, including those targeted by Omeros' treatments.

About

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Show more...
CEO
Gregory A. Demopulos
Employees
175
Country
United States
ISIN
US6821431029
WKN
000A0NBFF

Listings

LSE
GB
0KBU.LSE
MU
DE
3O8.MU
STU
DE
3O8.STU
F
DE
3O8.F

0 Comments

Share your thoughts

FAQ

What is Omeros stock price today?▼
The current price of OMER is $19.16 USD — it has increased by +0.21% in the past 24 hours. Watch Omeros stock price performance more closely on the chart.
What is Omeros stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Omeros stocks are traded under the ticker OMER.
Is Omeros stock price growing?▼
OMER stock has risen by +1.43% compared to the previous week, the month change is a +44.38% rise, over the last year Omeros has showed a +349.06% increase.
What is Omeros market cap?▼
Today Omeros has the market capitalization of 1.39B
When is the next Omeros earnings date?▼
Omeros is going to release the next earnings report on November 11, 2026.
What were Omeros earnings last quarter?▼
OMER earnings for the last quarter are 0.15 USD per share, whereas the estimation was -0.27 USD resulting in a +155.91% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Omeros revenue for the last year?▼
Omeros revenue for the last year amounts to 0 USD.
What is Omeros net income for the last year?▼
OMER net income for the last year is -3.35M USD.
How many employees does Omeros have?▼
As of September 09, 2026, the company has 175 employees.
In which sector is Omeros located?▼
Omeros operates in the Health & Wellness sector.
When did Omeros complete a stock split?▼
Omeros has not had any recent stock splits.
Where is Omeros headquartered?▼
Omeros is headquartered in SEATTLE, United States.